history of glp-1 agonists Another milestone in the evolution GLP-1-based diabetes therapies The expanding landscape of GLP-1

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Codeage GLP-1 Probiotic+ is carefully formulated to meet the needs of individuals with dietary restrictions

altRx GLP-1 Injections are customized GLP-1 therapy designed for individuals who benefit from a formulation aligned with their specific health goals

More prospective studiesare needed to validate and concentrate all guidelines and refine best practices in the era of metabolic pharmacology.

This bundle features our High-Potency Multi, formulated to address common nutrient deficiencies, and our Dual-Action Probiotic, which combines a clinically-studied probiotic strain, prebiotic fibre, and ginger to promote digestive comfort

Who it's for